Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TGRX-326 monotherapy in advanced ALK-positive non-small cell lung cancer after failure of second-generation ALK inhibitors
CTR20222981Phase 2Completed
- Sponsor
- Tajirui
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deulorlatinib in non-small cell lung cancer (NSCLC), sponsored by Tajirui. Started Jan 2023; status: completed.
02
Drugs
deulorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222981.